The vaccination push continues unabated? Nay, it is just beginning to gain momentum!
“New £3 jab 'could rid world of deadly malaria in just 10 years', Brit expert reveals” (The Mirror, 2024.02.18):
Prof Adrian Hill has helped create the vaccine that could be a game-changer in the fight against the mosquito-borne disease, which claims more than 600,000 lives a year.
The first successful vaccine, GSK’s RTS,S jab, also known as Mosquirix, was given approval by the World Health Organisation in July 2022. In December the WHO gave Oxford University’s R21 vaccine the OK. It is expected to be cheaper to produce as it will be made at the Serum Institute of India, which helped make the AstraZeneca Covid vaccine.
AstraZeneca?! I would have omitted that detail, if I was The Mirror.
What do we know about Prof Adrian Hill (not to be confused with Dr. Andrew Hill)? His previous area of excellence has been adenoviral vaccine vectors, incidentally one of which had been used in now infamous AstraZeneca, and also in the J&J deadly Covid jabs.
With this track record, we’d like to find out more about the new R21 vaccine technology, and here it is:
R21* is a protein-based investigational vaccine developed by the University of Oxford, using our Matrix-M™ adjuvant technology.
To recap:
A malaria-extracted circumsporozoite protein-coding gene is combined with the HBsAg Hepatitis B surface gene to code for the best of both worlds in the form of a DNA plasmid (more on them below).
The said plasmid is injected into a yeast cell.
The plasmid enters the yeast cell’s nucleus and injects the recombinant Malaria/HB gene in the cell’s DNA [remember we were told in 2020-2022 that mRNA jabs can never-ever get into your cells’ nuclei and alter your DNA, only in 2023 to find out that the jabs contained “impurities” in the form of cDNA plasmids?]. Somehow, this step in the article does not receive the attention it deserves?
The yeast cells churn out Malaria and HepB’s shell proteins until the yeast cells’ membranes get dissolved in the production process, releasing the proteins.
The expressed fused proteins self-assemble into the R21 “viral-like particles” - wicked! Another article from 2021 stipulates that this self-assembly happens inside the yeast cell, not after the cell has been killed by the lysis of its membrane.
Thus produced viral-like particles are mixed with a novel M-Matrix saponin adjuvant. So novel, in fact, that it has never been used in human vaccines up to this point. Yet, lots of novel “vaccines” are indifferent stages of pre-clinical trials at this moment. The article “The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century” (Hum Vaccin Immunother. 2023; 19(1): 2189885.
Published online 2023 Apr 27) proudly states that Matrix-M™ adjuvant is “achieving potent adjuvanticity with a favorable safety profile”. So favourable, in fact, that although being used in animal vaccines since 1970s, “this mixture of saponins, however, with varying adjuvant activity and toxicity was found to be too reactogenic for use in humans.” (“Evolution of adjuvants across the centuries”, Nathalie. Garçon, ... Martin. Friede, in Vaccines (Sixth Edition), 2013). Imagine that!
No matter, these Matrix-M reinforced jabs will be deployed as soon as they get waived through by the WHO, FDA and CDC, so stay tuned:
Back to R21 jabs. Its administration is already ongoing in Kameroon, soon to become massive, as The Sun reports in “MALARIA HOPE: Malaria can be wiped out in ten years with new jabs, mosquito nets & anti-malarial drugs, says Brit vaccine inventor” (2024.02.17):
The R21 jab costs £3 per dose and factories in India could ramp up production to 200 million per year. Routine injections began in Cameroon last month and health chiefs want to immunise 6.6 million children in 20 African countries by next year.
What could possibly go wrong?
For one, “inadvertent” administration of intact DNA plasmids as impurities in the malaria jab, similar to what happened in Covid mRNA jabs, if we have learned any lessons?
Second, the immonodominant repetitive domains in the circumsporozoite protein may act as an immune evasion vehicle, for whatever ends:
I refer you to the article itself (pp. 68-69) as what follows is pretty involved.
In Third, the HBsAg Hepatitis B surface gene is not a single entity but rather a whole family of similar subtypes:
The analysis indicated that a relatively hydrophilic region of the HBsAg protein, spanning amino acid residues 110 to 160, specifies the major (w) and (r) subtype system. The (w/r) subtype appears to depend on changes in one or more variable amino acids at positions 47, 110, 113, 126 and 160 of the HBsAg polypeptide.
So, what was the rationale of bringing the HebB surface protein into the malaria vaccine again, and which subtype thereof exactly?
Raises red flags in ones’ mind, doesn’t it?
Thanks for your time and let me know what you think!
P.S. If you wonder what the heck is the virus-like particle and why ever create one, have a look at this 2014 PhD thesis, “R21, a novel particle based vaccine for a multi-component approach to malaria vaccination”. It says on p.147:
Virus-like particles (VLPs) are formed from virus capsid or envelope proteins that have the ability to self-assemble into particulate structures resembling native virus or subviral particles. Generally, they present proteins in their natural confirmation and consist of highly ordered structures mimicking the native antigenic properties of a virus. They lack the viral genome and are therefore non-infectious but their size and structure means they can trigger strong cellular and humoral immune responses making them attractive vaccine candidates against viral infections
Translation: it’s size is like virus’s size, it looks like a virus, therefore it should trick your immune system to believe it’s a real virus. Hence the virus-like particles are a good idea.
One thing’s for sure, they scare hibigibies out of the immune systems. Somehow, this approach hasn’t been used in super-novel Covid jabs. But it has been applied in a HepB vaccine back in 1981:
The first VLP to be used as a vaccine was the hepatitis B surface antigen subviral particle (HBsAg) which is approximately 22nm in size (originally termed the Australian antigen). The particle is composed of around 30% hepatitis B surface envelope protein and 70% host lipids, and these particles were the main component of HEPTAVAX, the first hepatitis B vaccine licensed in 1981.
It was hard to manufacture from the serum of infected HepB subjects, but with the advances in the recombinant DNA technology a new life has been breathed into this approach.
There is complete detailed information on the R21 jab design in this thesis, as well as the process and result of animal testing. An interesting revelation is about the durability of protection conferred by the R21+Matrix-M combination, in mice (p. 253) :
The protection elicited by immunisation with R21 + Matrix M was also found to be relatively durable; when assessed at 7 and 14 weeks after vaccination, sterile protection remained high at 75% and 50%, respectively.
Just like Covid mRNA jabs!
"Game-changer" is a typical marketing slogan employed by pharma for decades, along with things like "magic bullet". That should be enough to warn us, if the fact that it's the same Oxford/AZ people.
thanks for the warning. the names alone will keep me from getting this jab! who wants to be poisoned by the witches brew?